210 related articles for article (PubMed ID: 30551404)
1. Reevaluation of the post-marketing safety of Xuebijing injection based on real-world and evidence-based evaluations.
Wang C; Shi QP; Ding F; Jiang XD; Tang W; Yu ML; Cheng JQ
Biomed Pharmacother; 2019 Jan; 109():1523-1531. PubMed ID: 30551404
[TBL] [Abstract][Full Text] [Related]
2. Reevaluation of the post-marketing safety of Shuxuening injection based on real-world and evidence-based evaluations.
Wang C; Shi QP; Ding F; Jiang XD; Tang W; Yu ML; Zhu JH
Drug Des Devel Ther; 2018; 12():757-767. PubMed ID: 29670332
[TBL] [Abstract][Full Text] [Related]
3. Safety of the Xuesaitong injection in China: results from a large-scale multicentre post-marketing surveillance study in a real-world setting.
He Y; Gao XM; Li L; Liu XG; Liu W; Hong XJ; Huang BH; Yang HL; Xue MH; Wu XJ; Liu JF
Curr Med Res Opin; 2020 Dec; 36(12):1947-1953. PubMed ID: 33016133
[TBL] [Abstract][Full Text] [Related]
4. [Differential analysis of different study types in clinical safety evaluation of Xuebijing Injection].
Li Q; Jin XY; Zhou X; Pang WT; Wang KY; Li N; Zheng WK
Zhongguo Zhong Yao Za Zhi; 2021 Feb; 46(3):712-721. PubMed ID: 33645039
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of questionable allergic factors to kudiezi injection--nested case control study using hospital information system data].
Liao X; Zeng XB; Xie YM; Yang W; Ai QH
Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(18):3559-62. PubMed ID: 25532395
[TBL] [Abstract][Full Text] [Related]
6. [Analysis of clinical use of post-marketing hospital centralized monitoring of Xiyanping injection].
Zhao Y; Shi C; Huang P
Zhongguo Zhong Yao Za Zhi; 2016 Feb; 41(4):743-747. PubMed ID: 28871704
[TBL] [Abstract][Full Text] [Related]
7. [Clinical safety studies based on 30 026 post-marketing cases of Shenqi Fuzheng injection by intensive hospital monitoring nested NCCS].
Wang LX; Xie YM; Ai QH; Xu WF
Zhongguo Zhong Yao Za Zhi; 2015 Dec; 40(24):4739-45. PubMed ID: 27245015
[TBL] [Abstract][Full Text] [Related]
8. Post-marketing safety surveillance and re-evaluation of Xueshuantong injection.
Li C; Xu T; Zhou P; Zhang J; Guan G; Zhang H; Ling X; Li W; Meng F; Liu G; Lv L; Yuan J; Li X; Zhu M
BMC Complement Altern Med; 2018 Oct; 18(1):277. PubMed ID: 30326892
[TBL] [Abstract][Full Text] [Related]
9. [Post-marketing surveillance of
Li XX; Zhuo L; Yang YH; Zhan SY; Zhai SD
Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Feb; 38(2):248-252. PubMed ID: 28231676
[No Abstract] [Full Text] [Related]
10. ["Re-evaluation upon suspected event" is an approach for post-marketing clinical study: lessons from adverse drug events related to Bupleuri Radix preparations].
Wu SX; Sun HF; Yang XH; Long HZ; Ye ZG; Ji SL; Zhang L
Zhongguo Zhong Yao Za Zhi; 2014 Aug; 39(15):2983-8. PubMed ID: 25423845
[TBL] [Abstract][Full Text] [Related]
11. [Study of post marketing safety reevaluation of shenqi fuzheng injection].
Ai QH; Li YY; Xie YM
Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(18):3633-6. PubMed ID: 25532410
[TBL] [Abstract][Full Text] [Related]
12. Establishment of safety evidence for Xingxue Shuxuening injection.
Yang W; Zhang W; Xie Y; Han B
J Tradit Chin Med; 2014 Oct; 34(5):604-8. PubMed ID: 25417413
[TBL] [Abstract][Full Text] [Related]
13. [Predictive analysis on Shenmai injection-induced adverse reactions with Logistic model and ROC curve].
Ding F; Shi QP; Jiang XD; Liu Y; Sang R; Zhu JX; Wei ST; Xin ZM; Song R
Zhongguo Zhong Yao Za Zhi; 2015 Apr; 40(7):1404-9. PubMed ID: 26281570
[TBL] [Abstract][Full Text] [Related]
14. [The effect of Xuebijing injection for severe acute pancreatitis: a Meta analysis].
Zheng R; Zhang L; Tian R; Li N; Lei X; Jing L; Liu S; Feng Z; Shou S; Shang H
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2015 Aug; 27(8):682-6. PubMed ID: 26255019
[TBL] [Abstract][Full Text] [Related]
15. [Nested case control study to analyze suspected cases and their related factors of allargic reactions to parenterally administered dengzhan xixin].
Yang W; Cheng H; Xie YM; Yang H; Zhuang Y
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):3024-7. PubMed ID: 24471324
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of rational clinical uses of traditional Chinese medicine injections and factors influencing adverse drug reactions].
Sun SG; Li ZF; Xie YM; Liu J; Lu Y; Song YF; Han YH; Liu LD; Peng TT
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2969-73. PubMed ID: 24471313
[TBL] [Abstract][Full Text] [Related]
17. Safety of traditional Chinese medicine injection based on spontaneous reporting system from 2014 to 2019 in Hubei Province, China.
Huang R; Cai Y; Yang L; Shangguan X; Ghose B; Tang S
Sci Rep; 2021 Apr; 11(1):8875. PubMed ID: 33893351
[TBL] [Abstract][Full Text] [Related]
18. Analysis and study on 47 cases of adverse reactions of Chinese medicine injection.
Zhang X; Sang D; Zhang Z; Kong S
Afr J Tradit Complement Altern Med; 2014; 11(2):363-4. PubMed ID: 25435623
[TBL] [Abstract][Full Text] [Related]
19. Post-marketing safety monitoring of shenqifuzheng injection: a solution made of dangshen (Radix Codonopsis) and huangqi (Radix Astragali Mongolici).
Ai Q; Zhang W; Xie Y; Huang W; Liang H; Cao H
J Tradit Chin Med; 2014 Aug; 34(4):498-503. PubMed ID: 25185371
[TBL] [Abstract][Full Text] [Related]
20. [A prospective multicenter clinical study of Xuebijing injection in the treatment of sepsis and multiple organ dysfunction syndrome].
Gao J; Kong L; Liu S; Feng Z; Shen H; Liu Q;
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2015 Jun; 27(6):465-70. PubMed ID: 26049185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
